Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience

By Pittman P.R.   Liu C.T.   Cannon T.L.   Makuch R.S.   Mangiafico J.A.   Gibbs P.H.   Peters C.J.  

Vaccine, Vol. 18, Iss. 1, 1999-08 ,pp. : 181-189

Elsevier

Access to resources Recommend Favorite

Immunogenicity of a pilot inactivated poliovirus vaccine with trypsin-treated type 3-component

By Piirainen L.   Roivainen M.   Litmanen L.   Eskola J.   Beuvery E.C.   Hovi T.  

Vaccine, Vol. 15, Iss. 2, 1997-02 ,pp. : 237-243

Elsevier

Access to resources Recommend Favorite

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans

By Pittman P.R.   Kim-Ahn G.   Pifat D.Y.   Coonan K.   Gibbs P.   Little S.   Pace-Templeton J.G.   Myers R.   Parker G.W.   Friedlander A.M.  

Vaccine, Vol. 20, Iss. 9, 2002-01 ,pp. : 1412-1420

Elsevier

Access to resources Recommend Favorite

DNA vaccination protects against botulinum neurotoxin type F

By Bennett A.M.   Perkins S.D.   Holley J.L.  

Vaccine, Vol. 21, Iss. 23, 2003-07 ,pp. : 3110-3117

Elsevier

Access to resources Recommend Favorite

Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response

By Dockrell D.H.   Poland G.A.   Steckelberg J.M.   Wollan P.C.   Strickland S.R.   Pomeroy C.  

Vaccine, Vol. 17, Iss. 22, 1999-07 ,pp. : 2779-2785

Elsevier

Access to resources Recommend Favorite